APOC3, Coronary Disease, and Complexities of Mendelian Randomization

作者：Cohen Jonathan C^*; Stender Stefan; Hobbs Helen H

来源：Cell Metabolism, 2014, 20(3): 387-389.

DOI：10.1016/j.cmet.2014.08.007

Two new studies report that triglyceride (TG)-lowering mutations in APOC3 reduce coronary heart disease (CHD) (Crosby et al., 2014; Jorgensen et al., 2014). Here, we explore limitations of using Mendelian randomization to evaluate CHD risk, including potential confounding by the widespread use of statin therapy.

• 出版日期2014-9-2